Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Evaluating antibiotic use before onabotulinumtoxinA injections for overactive bladder

Official title: Optimizing Antibiotic Use in Treatment of Overactive Bladder: Evaluating the Need for Prophylactic Antibiotics Prior to OnabotulinumtoxinA Injection in Patients Without Urinary Tract Infection

Run by Benaroya Research Institute · NCT04754737 · Data updated 2026-11-12

This study is testing if giving antibiotics before onabotulinumtoxinA injections helps or is needed for adults with overactive bladder who haven't found relief from other treatments.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment200 (estimated)
SponsorBenaroya Research Institute
Academic / other
Locations1 site (Stony Brook, New York)
StatusRecruiting
StartedMarch 23, 2021
Main results expectedDecember 2025
Study endsDecember 2026
Registry record updatedMay 24, 2024
Trial IDNCT04754737 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 and older diagnosed with OAB who have failed first and second line therapies.

Probably not a fit

Patients who have recently used antibiotics or are symptomatic for UTIs will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the necessity of prophylactic antibiotics prior to intradetrusor injections of onabotulinumtoxinA in patients with overactive bladder (OAB). It aims to optimize antibiotic usage by comparing outcomes between patients receiving antibiotics and those who do not. The study includes adults diagnosed with OAB who have not responded to standard therapies and ensures participants are not symptomatic for urinary tract infections (UTIs) at the time of injection. By addressing the appropriateness of antibiotic use, the study seeks to reduce unnecessary complications associated with antibiotic therapy.

Why it matters

Potential benefit: If successful, this study could lead to more effective management of antibiotic use, reducing the risk of complications and antibiotic resistance in patients undergoing treatment for OAB.

How similar studies have gone: While studies have shown success in antibiotic stewardship in other surgical contexts, this specific approach to OAB treatment is novel and untested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥ 18
* Diagnosis of OAB who have failed 1st and 2nd line therapies per the AUA/SUFU OAB guidelines (including bladder training, dietary modification and pharmacotherapy with an anticholinergic and/or beta-3 agonist)
* Not symptomatic for UTI at the time of injection
* Negative urinalysis at the time of the injection defined as: negative for nitrites and leukocyte esterace, with urine white blood cell count less than 5 per high-power field
* Consent to participate in the study.

Exclusion Criteria:

* Antibiotic usage within 48 hours prior to intradetrusor onabotulinumtoxinA injection
* Women who are pregnant or planning to become pregnant, women who are breastfeeding
* Concurrent use of onabotulinumtoxinA injection with maximum cumulative dose exceeding 400 units in a 3-month interval.

Where it's running

  • Stony Brook Medicine
    Stony Brook, New York, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.